PVLAHIGH SIGNALFINANCIAL10-K

PVLA shows severe financial deterioration with R&D expenses nearly tripling to $22.8M, operating losses expanding 174% to -$38.6M, and stockholders' equity declining 55% to $28.0M despite 65% revenue growth.

The company is burning cash at an unsustainable rate with operating cash flow worsening to -$25.0M, suggesting potential funding needs in the near term. While revenue growth of 65% is positive, it's being overwhelmed by explosive R&D spending increases, indicating either aggressive expansion or inefficient capital allocation that threatens financial stability.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

PVLA's financials show a company in aggressive expansion mode with revenue growing 65% to $42.8M, but this growth is overshadowed by R&D expenses nearly tripling to $22.8M and interest expense surging 437% to $2.7M. The company's financial position has deteriorated significantly with stockholders' equity declining 55% to $28.0M, total assets shrinking 33%, and operating cash flow losses more than doubling to -$25.0M. This pattern suggests unsustainable cash burn that will likely require additional financing to maintain operations.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+437.5%
$494K→$2.7M

Interest expense surged 437.5% — significant debt increase or rising rates materially impacting earnings.

R&D Expense
P&L
+180.2%
$8.2M→$22.8M

R&D investment increased 180.2% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
-173.9%
-$14.1M→-$38.6M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-139.3%
-$17.4M→-$41.7M

Net income declined 139.3% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-130.7%
-$10.8M→-$25.0M

Operating cash flow fell 130.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Capital Expenditure
Cash Flow
-83.6%
$1.0M→$171K

Capex reduced 83.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Revenue
P&L
+65.3%
$25.9M→$42.8M

Strong top-line growth of 65.3% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
-55.3%
$62.6M→$28.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-33.1%
$88.2M→$59.0M

Current assets declined 33.1% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-32.5%
$88.2M→$59.6M

Total assets contracted 32.5% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
The rare skin diseases and vascular malformations we are currently targeting have no U.S.
Our lead product candidates are based on our QTORIN platform and we are consequentially highly dependent on the successful development of this novel and unproven technology.
Orphan Drug Designation has been granted for QTORIN rapamycin for the treatment of microcystic lymphatic malformation (microcystic LM), but we may be unable to obtain such designation for other product candidates or to realize the benefits of Orphan Drug Designation, including potential marketing exclusivity, even if such designation is obtained.
Our development and commercialization strategy for our product candidates depends, in part, on published scientific literature and the FDA s prior findings regarding the safety and efficacy of rapamycin, pitavastatin, and other planned or future product candidates.
Breakthrough Therapy Designation has been granted for QTORIN rapamycin for the treatment of microcystic LM but we may never be able to realize the benefits of such designation for QTORIN rapamycin or any other indications or future product candidates, if granted, and such designation may not lead to a faster development, regulatory review or approval process or increase the likelihood that our product candidates will receive marketing approval.
+7 more — sign up free →
REMOVED
The rare genetic skin diseases we are currently targeting have no U.S.
Our lead product candidates are based on our QTORIN platform, which is highly dependent on the successful development of this novel and unproven technology.
We may be unable to obtain Orphan Drug Designation for certain of our product candidates and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved.
Our development and commercialization strategy for our product candidates depends, in part, on published scientific literature and the FDA s prior findings regarding the safety and efficacy of rapamycin.
Fast Track Designation granted for QTORIN rapamycin for the treatment of microcystic lymphatic malformation (microcystic LM) and, if granted by the FDA, for any of our other product candidates may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →